Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Journey Medical CorporationNASDAQ: DERM

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $1.15M rose 5.8% year over year, behind the +17.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 5.6% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.

Context

  • Depreciation & amortization amounted to 7.6% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.8% toward the trailing-twelve-month pace of +17.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.15M+5.6% QoQ
Last fiscal yearDec 2025
$4.72M+38.0% YoY
LTMMar 2026
$4.41M+17.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.8%——
1 year+38.0%——
3-year CAGR+2.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
4.72M USD
Year-over-year change
+38.0%
4-year CAGR
+16.6%

Depreciation & Amortization vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.1% is the 5th highest of 10, against a peer median of +13.1%.
  • Depreciation & amortization amounts to 6.8% of revenue for DERM, versus a peer median of 8.7%.
DERM Competitors
Depreciation & Amortization for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGIOrganigram Global Inc.LTM Mar 2026CA$19.77M CAD+37.9%—7.2%
OSUROraSure Technologies, Inc.LTM Mar 2026$9.86M USD-9.2%-91.3%8.7%
NYXHNyxoah S.A.LTM Mar 2026€5.43M EUR+88.5%+32.4%33.3%
DERMJourney Medical CorporationLTM Mar 2026$4.41M USD+17.1%+2.7%6.8%
IVAInventiva S.A.FY2025€3.22M EUR-38.0%+23.8%71.9%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$2.42M USD+13.1%+32.0%136.2%
MDWDMediWound Ltd.LTM Mar 2026$1.88M USD+27.6%+10.4%13.0%
HSDTSolana CompanyLTM Mar 2026$672K USD+1192.3%+30.5%7.0%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$334K USD+5.4%+13.8%1.0%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$103K USD-59.6%-11.6%0.2%
Peer median (excluding DERM) —+13.1%+18.8%8.7%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Depreciation & Amortization2.56M4.37M3.86M3.42M4.72M
Deferred Income Tax1.57M0000
Stock-Based Compensation2.47M4.43M2.61M6.1M6.29M
Change in Working Capital14.71M6.19M(1.66M)(3.77M)(11.9M)
Accounts Receivables768K(5.38M)12.55M4.48M(19.34M)
Inventory(8.46M)1.74M3.95M(4.23M)4.81M
Accounts Payables21.71M14.34M(18.42M)(2.1M)(7.27M)
Other Working Capital686K(4.52M)262K(1.92M)9.91M
Other Non-Cash Items20.51M1.12M4.29M(211K)(123K)
Operating Cash Flow(2.18M)(13.53M)5.24M(9.13M)(12.44M)
Capital Expenditures(10M)(20M)(5M)(15M)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(10M)(20M)(5M)(15M)0
Debt Repayment5.05M16.9M(8.95M)8.7M15.73M
Common Stock Issued32.54M142K4.49M8.29M16.93M
Common Stock Repurchased0(371K)000
Dividends Paid00000
Other Financing Activities16.97M(214K)(350K)(50K)(16.43M)
Financing Cash Flow53.02M16.46M(4.8M)16.99M16.23M
Effect of Forex Changes00000
Net Change in Cash40.84M(17.08M)(4.56M)(7.13M)3.79M
Free Cash Flow(12.18M)(33.53M)240K(9.13M)(12.44M)

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.